Year None202220212020201920182017 Oct 04, 2022 Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress Sep 29, 2022 Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions Sep 29, 2022 Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences Sep 06, 2022 Tenaya Therapeutics to Participate in Upcoming September Investor Conferences Sep 06, 2022 Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction Aug 10, 2022 Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update Jul 06, 2022 Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure Jun 16, 2022 Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics May 20, 2022 Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference May 11, 2022 Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 16
Oct 04, 2022 Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress
Sep 29, 2022 Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions
Sep 29, 2022 Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences
Sep 06, 2022 Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction
Aug 10, 2022 Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Jul 06, 2022 Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure
Jun 16, 2022 Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics
May 20, 2022 Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference
May 11, 2022 Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
